Skip to main content

Elopag 20 mg ( Eltrombopag)

Introduction

Reliable medical information should be supported by appropriate pharmaceutical, regulatory and clinical references. This is particularly important for prescription medicines such as Elopag, which contains eltrombopag, an oral thrombopoietin receptor agonist used in selected patients with conditions involving low platelet counts.

This reference page identifies important sources for understanding Elopag, its active ingredient, manufacturer information, medical uses, administration requirements, potential adverse reactions and safety precautions.

The references are organized according to their purpose so that readers can distinguish between manufacturer-specific product information, official regulatory documents and general medical literature.

A key distinction is that information about eltrombopag as an active ingredient does not automatically verify every detail of a particular branded product. Elopag-specific manufacturer information should be checked against the original product documentation.

1. Official Manufacturer Reference

Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is identified as the manufacturer of Elopag in its published product catalogue.

Its hematology product listing identifies:

  • Elopag 25 – Eltrombopag INN 25 mg.
  • Elopag 50 – Eltrombopag INN 50 mg.

The manufacturer’s catalogue is an important primary source for checking the brand name, listed strengths and manufacturer-associated product information.

For website content, manufacturer documentation should be prioritized when discussing:

  • Product identity.
  • Brand-specific strengths.
  • Dosage form.
  • Packaging information.
  • Approved product leaflet.
  • Batch-related inquiries.
  • Storage instructions.
  • Manufacturer details.

Important strength clarification: The published manufacturer catalogue identifies Elopag 25 mg and Elopag 50 mg. Elopag 20 mg has not been established by this source and should not be presented as a verified strength without further documentation.

2. U.S. Food and Drug Administration (FDA)

The U.S. Food and Drug Administration is an important regulatory source for prescription medicine information.

Its prescribing information for PROMACTA, the U.S. reference brand of eltrombopag, provides detailed information about the medicine’s clinical uses, dosage, warnings, contraindications, adverse reactions and monitoring requirements.

Information available in the FDA prescribing document

The prescribing information covers:

  • Approved indications.
  • Dosage and administration.
  • Dosage forms and strengths.
  • Warnings and precautions.
  • Liver toxicity.
  • Thrombotic and thromboembolic complications.
  • Adverse reactions.
  • Drug interactions.
  • Use in special populations.
  • Clinical pharmacology.
  • Patient counseling information.

The FDA reference label is useful for understanding the established safety and prescribing considerations associated with eltrombopag.

However, PROMACTA is a separate branded product. Its U.S. prescribing instructions should not automatically be treated as the approved instructions for Elopag in Bangladesh or another country.

3. DailyMed – U.S. National Library of Medicine

DailyMed is a resource providing structured information about marketed human prescription and non-prescription drug labeling in the United States.

It contains medicine labeling records, including information for eltrombopag products.

Why DailyMed is useful

DailyMed can help readers and healthcare professionals review:

  • Active ingredients.
  • Dosage forms.
  • Available strengths.
  • Indications and usage.
  • Dosage instructions.
  • Warnings and precautions.
  • Adverse reactions.
  • Drug interactions.
  • Clinical pharmacology.
  • Patient information.

DailyMed is particularly useful for checking the details of current U.S. product labeling.

Different manufacturers may have separate labeling records. Readers should identify the correct product and label rather than assuming that all eltrombopag products have identical packaging or product-specific instructions.

4. European Medicines Agency (EMA)

The European Medicines Agency provides regulatory and scientific information about medicines authorized in the European Union.

Its European Public Assessment Report for REVOLADE contains information about eltrombopag, including its therapeutic uses, mechanism of action, clinical evidence and product information.

Information available from the EMA

The EMA reference material discusses:

  • The active substance eltrombopag.
  • Immune thrombocytopenia.
  • Severe aplastic anemia.
  • Chronic hepatitis C-associated thrombocytopenia in applicable treatment settings.
  • Dosage and administration.
  • Safety considerations.
  • Clinical studies.
  • Benefit-risk assessment.
  • Product information.

The EMA documentation is useful for understanding the European regulatory assessment of eltrombopag.

However, REVOLADE is not the same brand as Elopag. Its European authorization should not be interpreted as proof of Elopag’s registration or approval in another jurisdiction.

5. Bangladesh Directorate General of Drug Administration (DGDA)

The Directorate General of Drug Administration is Bangladesh’s national medicines regulatory authority.

Its regulatory responsibilities include medicine registration, licensing, quality oversight and regulatory monitoring.

For Elopag-related website information, the DGDA is an important source for checking applicable national regulatory requirements.

Information to verify

Readers and website administrators should consider checking:

  • Whether the relevant product is registered.
  • The approved brand name.
  • The approved manufacturer.
  • The authorized strengths.
  • The approved dosage form.
  • Applicable manufacturing and marketing requirements.
  • Relevant safety or regulatory notices.

A product’s appearance in a manufacturer’s catalogue or commercial medicine directory should not be treated as a substitute for official regulatory confirmation.

6. MedEx Bangladesh – Medicine Reference Information

MedEx Bangladesh provides medicine reference information, including generic names, brand names, manufacturers, dosage forms and product strengths.

Its eltrombopag olamine brand listing identifies Elopag 25 mg and Elopag 50 mg under Everest Pharmaceuticals Ltd.

This source can be useful for preliminary brand and product comparisons.

However, MedEx is a secondary medicine information resource, not the national medicines regulatory authority. Product authorization, prescribing instructions and current availability should be confirmed through the appropriate primary sources.

7. World Health Organization (WHO)

The World Health Organization provides international guidance concerning medicine quality, safety and access to essential medicines.

Its work on substandard and falsified medical products is relevant to responsible medicine purchasing and product verification.

Topics relevant to Elopag product safety

WHO resources can help readers understand:

  • Substandard medicines.
  • Falsified medicines.
  • Pharmaceutical quality assurance.
  • Medicine supply-chain risks.
  • Safe medicine handling.
  • The importance of authorized supply channels.
  • Reporting suspected falsified medical products.

These resources are particularly relevant when evaluating medicine packaging or investigating a product obtained from an uncertain supply source.

WHO guidance does not independently authenticate an individual Elopag package.

8. Clinical and Medical References for Eltrombopag

Eltrombopag has been studied in several medical conditions involving impaired platelet production or low platelet counts.

Clinical research and professional treatment guidelines help explain the evidence supporting its use.

Important areas of clinical research include:

Immune thrombocytopenia

Research has evaluated eltrombopag in patients with persistent or chronic immune thrombocytopenia who have not responded adequately to certain previous treatments.

Clinical literature examines platelet response, bleeding-related outcomes, treatment duration and adverse reactions.

Severe aplastic anemia

Studies have evaluated eltrombopag in selected patients with severe aplastic anemia, including treatment approaches involving immunosuppressive therapy and patients with inadequate responses to previous treatment.

Chronic hepatitis C-associated thrombocytopenia

Clinical research has also examined eltrombopag in specific chronic hepatitis C treatment settings where low platelet counts may interfere with antiviral therapy.

The relevance of these studies depends on the applicable treatment guidelines and regulatory authorization.

Clinical study findings should not be interpreted as proof that every indication is approved for every eltrombopag brand.

9. Pharmacological References

Eltrombopag belongs to the thrombopoietin receptor agonist class.

It activates the thrombopoietin receptor, also known as c-Mpl, and supports the development and maturation of megakaryocytes, the bone marrow cells responsible for producing platelets.

Pharmacological references help explain:

  • Mechanism of action.
  • Receptor activity.
  • Absorption.
  • Distribution.
  • Metabolism.
  • Elimination.
  • Food interactions.
  • Mineral interactions.
  • Dose-related considerations.

These details are useful for explaining how eltrombopag works and why administration instructions and monitoring are important.

10. Safety and Monitoring References

Eltrombopag treatment requires appropriate medical supervision and laboratory monitoring.

Official prescribing documents and clinical guidance should be consulted for information about:

Liver function

Eltrombopag may cause liver enzyme abnormalities and clinically significant liver injury. Prescribing information describes the need for liver function assessment before and during treatment.

Platelet counts

Platelet monitoring helps healthcare professionals assess treatment response and adjust the dose appropriately.

The objective is generally to achieve a platelet count sufficient to reduce bleeding risk rather than unnecessarily normalize the count.

Thrombotic complications

Eltrombopag is associated with thrombotic and thromboembolic risks. Medical references discuss the need to assess individual risk factors and monitor patients appropriately.

Drug interactions

Reference prescribing documents describe interactions with products containing polyvalent cations, including calcium, iron, magnesium, aluminium and zinc.

These substances may reduce eltrombopag absorption when taken too close to the medicine.

11. Reference Source Summary

The following table explains the main purpose of each reference.

Reference sourceMain purposeSource type
Everest Pharmaceuticals Ltd.Elopag brand and listed strengthsManufacturer
FDAPROMACTA prescribing informationRegulatory
DailyMedU.S. medicine labelingDrug-label database
EMAREVOLADE product information and assessmentRegulatory
Bangladesh DGDANational medicine regulationRegulatory
MedEx BangladeshBrand and generic medicine informationSecondary medicine reference
WHOMedicine quality and falsified-product guidanceInternational health organization
Published clinical studiesTreatment evidence and clinical outcomesScientific literature

12. How These References Are Used on This Website

The references listed on this page support the preparation and review of educational content about Elopag and eltrombopag.

Different sources serve different purposes.

Product-specific information

The Everest Pharmaceuticals product catalogue is used to identify the listed Elopag strengths and manufacturer-associated product information.

General medicine information

FDA, DailyMed and EMA documents provide information about eltrombopag and established reference products.

Regulatory information

The relevant national medicines regulatory authority should be consulted for country-specific registration and authorization details.

Safety information

Official prescribing information and clinical references support discussions of warnings, adverse reactions, monitoring and drug interactions.

Product authenticity

Manufacturer confirmation and applicable regulatory processes are more appropriate for investigating individual product packaging and batch information than general medical articles.

13. Important Limitations of the References

Readers should understand several important distinctions:

  1. A reference product’s prescribing information is not automatically the approved leaflet for Elopag.
  2. Regulatory approvals may differ between countries.
  3. A manufacturer’s product catalogue does not independently authenticate an individual package.
  4. Secondary medicine directories may not always reflect the latest regulatory changes.
  5. Clinical studies do not necessarily establish an approved indication for every branded product.
  6. Product-specific storage, formulation and packaging details must be confirmed using the actual approved documentation.
  7. The manufacturer’s published catalogue lists Elopag 25 mg and 50 mg; a 20 mg Elopag presentation requires additional verification.

These distinctions help ensure that medical information is presented accurately and responsibly.

Frequently Asked Questions About Elopag References

Where can I find official information about Elopag?

The manufacturer’s published product catalogue is a primary reference for Elopag’s listed strengths and manufacturer-associated product information. The approved product leaflet should be consulted for detailed product-specific instructions.

Who manufactures Elopag?

Everest Pharmaceuticals Ltd. identifies Elopag 25 mg and Elopag 50 mg in its hematology product catalogue.

Where can I find eltrombopag prescribing information?

The FDA prescribing information for PROMACTA and the EMA product information for REVOLADE are important regulatory references for eltrombopag.

Is PROMACTA the same product as Elopag?

No. They are different brand names associated with eltrombopag. Their manufacturer, packaging, regulatory authorization and product-specific instructions may differ.

What strengths of Elopag are listed by the manufacturer?

The published Everest Pharmaceuticals catalogue identifies Elopag 25 mg and Elopag 50 mg.

Is Elopag 20 mg verified?

The manufacturer’s published catalogue does not list Elopag 20 mg. Additional product documentation and regulatory confirmation are needed before describing this strength as verified.

What is the role of the DGDA?

The Directorate General of Drug Administration regulates medicines in Bangladesh, including relevant registration and licensing requirements.

Why are FDA and EMA references included?

These organizations publish regulatory and scientific information about established eltrombopag products. Their documents help explain the active ingredient, approved uses and safety considerations, but do not establish the authorization of Elopag itself.

Can clinical studies replace a doctor’s advice?

No. Clinical studies provide evidence about medicines, but treatment decisions must consider an individual patient’s diagnosis, medical history, laboratory results and clinical condition.

Why should website references be updated?

Medical evidence, product labeling, safety warnings and regulatory requirements can change. References should be reviewed periodically to maintain accuracy.

Medical Disclaimer

This reference page is provided for educational and informational purposes only. It does not replace professional medical advice, diagnosis, treatment or official product documentation.

References to PROMACTA, REVOLADE and other eltrombopag products describe information about those specific products or the active ingredient. They should not be interpreted as confirmation that every indication, dosage instruction or safety statement applies identically to Elopag.

Patients should consult a qualified healthcare professional and follow the approved product information applicable to their medicine and country.

Reference Bibliography

  1. Everest Pharmaceuticals Ltd. – Hematology Product Catalogue: Elopag 25 and Elopag 50.
  2. U.S. Food and Drug Administration – PROMACTA (eltrombopag) Full Prescribing Information, revised June 2025.
  3. U.S. National Library of Medicine – DailyMed: Eltrombopag and PROMACTA Drug Labeling.
  4. European Medicines Agency – REVOLADE European Public Assessment Report.
  5. European Medicines Agency – REVOLADE Product Information.
  6. Directorate General of Drug Administration, Bangladesh – National Medicines Regulatory Information.
  7. MedEx Bangladesh – Eltrombopag Olamine: Available Brand Names and Product Information.
  8. World Health Organization – Substandard and Falsified Medical Products: Guidance and Information.
  9. Published peer-reviewed clinical research on eltrombopag in immune thrombocytopenia.
  10. Published peer-reviewed clinical research on eltrombopag in severe aplastic anemia.

Reference Review Statement: Product-specific information should be checked against the latest available manufacturer documentation and applicable national regulatory records. General eltrombopag references should not be used as a substitute for Elopag’s approved prescribing information.